These reports describe counts, prevalence, and incidence of antipsychotic drug products in the Sentinel Distributed Database (SDD).
Sentinel routine querying tools are SAS programs designed to run against the Sentinel Common Data Model (SCDM). They allow rapid implementation of standard queries across the Sentinel Distributed Database (SDD). The programs can be customized using various input parameters that define medical product exposures, outcomes, covariates, diagnoses, date ranges, age ranges, and other implementation details. Tools can perform simple cohort characterization and descriptive analyses, but may also be used to perform more complex adjustment for confounding and support prospective surveillance activities.
The Cohort Identification and Descriptive Analysis (CIDA) program is the foundation of the routine querying system. CIDA is responsible for identifying, extracting, and characterizing cohorts of interest from the SDD based on the specification of a number of requester-defined options (e.g., continuous enrollment requirements, incidence criteria, inclusion/exclusion criteria).
The goal of this query was to examine the association between stent implants, intranasal steroids, oral steroids, and sinus surgery and subsequent development of diminished visual acuity, glaucoma, cataracts, or blindness in the Sentinel Distributed Database (SDD).
These reports contain the estimated rates of seizures among indiviuals exposed to ranolazine alone, as well as individuals with concomitant use of ranolazine and either beta blockers, selected oral calcium channel blockers, or non-injectable nitrates.
Protocol-based one-time assessment to determine the average change in body mass index (BMI) z-score among youth initiating monotherapy treatment with olanzapine, quetiapine or risperidone compared to aripiprazole between baseline (treatment initiation) and: (i) 12 weeks (+/- 2 weeks), and (ii) 52 weeks (+/- 8 weeks) in the Mini-Sentinel Distributed Database (MSDD) population.
The goal of this query was to estimate the proportion of incident oxycodone and oxymorphone users concomitantly using a selection of cytochrome P450 (CYP) enzyme inhibitors and inducers in the Sentinel Distributed Database (SDD).
This White Paper addresses compliance under the Health Insurance Portability and Accountability Act (“HIPAA”) and the Common Rule for data sources participating in the Sentinel Initiative.
The Sentinel Data Quality Review and Characterization Programs are used by the Sentinel Operations Center (SOC) for data quality review and characterization of the Sentinel Distributed Database (SDD). To create the SDD, each Data Partner transformed local source data into the Sentinel Common Data Model (SCDM) format. The SOC created a set of data quality review and characterization programs to ensure that the SDD meets reasonable standards for data transformation consistency and quality and that the SDD data meets expectations needed for a distributed health data network.
The Sentinel Operations Center (SOC) coordinates the network of Sentinel Data Partners and leads development of the Sentinel Common Data Model (SCDM), a standard data structure that allows Data Partners to quickly execute distributed programs against local data.